Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) – Equities researchers at Oppenheimer lowered their FY2021 EPS estimates for shares of Actinium Pharmaceuticals in a report issued on Wednesday, November 28th. Oppenheimer analyst H. Singh now expects that the biotechnology company will earn $0.46 per share for the year, down from their prior estimate of $0.51. Oppenheimer has a “Buy” rating and a $5.00 price objective on the stock. Oppenheimer also issued estimates for Actinium Pharmaceuticals’ FY2022 earnings at $1.68 EPS.
ATNM has been the subject of several other reports. Maxim Group reiterated a “buy” rating and set a $3.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, August 14th. Roth Capital set a $6.00 price target on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 8th. Finally, B. Riley set a $3.00 price target on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 15th. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $3.55.
Shares of Actinium Pharmaceuticals stock opened at $0.57 on Friday. Actinium Pharmaceuticals has a 52-week low of $0.33 and a 52-week high of $0.87.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Actinium Pharmaceuticals by 6.4% during the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock worth $1,909,000 after buying an additional 154,403 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Actinium Pharmaceuticals by 103.1% during the third quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock worth $146,000 after buying an additional 99,318 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $617,000. Essex Investment Management Co. LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $816,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Actinium Pharmaceuticals by 1,269.5% during the second quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock worth $248,000 after buying an additional 359,205 shares during the last quarter.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Featured Article: Fundamental Analysis and Individual Investors
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.